Journal
JOURNAL OF BONE AND MINERAL RESEARCH
Volume 25, Issue 1, Pages 2-10Publisher
JOHN WILEY & SONS INC
DOI: 10.1359/jbmr.091201
Keywords
BISPHOSPHONATES; ATRIAL FIBRILLATION; CALCIUM; MAGNESIUM; ZINC; METALLOPROTEINASES; INFLAMMATION, STATINS
Categories
Funding
- Cambridge Biomedical Research Centre
- National Institutes for Health Research (NHIR)
- Wellcome Trust
- Medical Research Council
- British Heart Foundation
Ask authors/readers for more resources
Bisphosphonates are the most commonly used treatment for osteoporosis and have proven efficacy in the reduction of vertebral and nonvertebral fractures. Recently, concerns have been raised about a possible association between bisphosphonate therapy and atrial fibrillation (AF) following the report of a significant increase in risk of serious AF in women treated with zoledronic acid in the HORIZON study. Subsequent studies have produced conflicting results but have not excluded the possibility of such an association. Currently there is no direct evidence that bisphosphonates exert either acute or chronic effects on cardiac electrophysiology. Nevertheless, altered intracellular electrolyte homeostasis and proinflammatory, profibrotic, and antiangiogenic effects provide potential mechanisms by which atrial conduction could be affected in patients treated with bisphosphonates. In studies in which an increase in risk of AF has been identified, there is no evidence that this translates into increased mortality or increased risk of stroke, and the risk-benefit balance of bisphosphonate therapy in patients with osteoporosis and other forms of metabolic bone disease remains strongly positive. (C) 2010 American Society for Bone and Mineral Research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available